Posted by Michael Wonder on 09 May 2020
European Commission approves subcutaneous formulation of Entyvio (vedolizumab) for use as maintenance therapy in adults with moderately to severely active ulcerative colitis or Crohn’s disease
8 May 2020 - Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease.
Takeda today announced that the European Commission has granted a marketing authorisation for the subcutaneous formulation of Entyvio (vedolizumab), a gut-selective biologic for use as maintenance therapy in adults with moderately to severely active ulcerative colitis or Crohn’s disease.
Entyvio subcutaneous will be made available in both a pre-filled syringe and a pre-filled pen.
